Clinical Trials · NCT07172867
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
- Phase
- Phase 2
- Recruitment status
- Withdrawn
- Sponsor
- Halia Therapeutics, Inc.
- Enrollment
- 0
- Start date
- Jan 2026
- Locations
- 1 site, United Arab Emirates
- Primary endpoint
- Assess glycemic control using HbA1c (%)